Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 4:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 169 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Tuberculosis, Mycobacterium Infection Clear all
Completed No phase listed Observational

Effect of Filarial Infection on Immune Responses in Latent Tuberculosis

NCT01547884
View directory record Official record
Conditions
Mycobacterium Infections, Tuberculosis, Filariasis, Latent Tuberculosis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
4,268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 10, 2026, 4:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Safety, Tolerability, and Blood Levels of Ritonavir-Boosted Atazanavir and Rifampin When Taken Together in HIV Uninfected Adults

NCT00096850
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Atazanavir, Rifampin, Ritonavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2007
U.S. locations
3
States / cities
Palo Alto, California • Columbus, Ohio • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 10, 2026, 4:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Escalating Single-dose Safety, Tolerability, and Pharmacokinetics of SQ109 in Healthy Volunteers

NCT01585636
View directory record Official record
Conditions
Tuberculosis
Interventions
SQ109
Drug
Lead sponsor
Sequella, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2013 · Synced Oct 10, 2026, 4:50 PM EDT
Completed Phase 2 Interventional

TBTC Study 23C: Pharmacokinetics of Intermittent Rifabutin and Isoniazid With Daily Efavirenz

NCT00023413
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Rifabutin, Efavirenz
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Oct 10, 2026, 4:50 PM EDT
Completed Not applicable Interventional

Preventive Treatment Against Tuberculosis (TB) in Patients With Human Immunodeficiency Virus (HIV) Infection and Confirmed Latent Tuberculous Infection

NCT00000638
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Isoniazid, Pyrazinamide, Pyridoxine hydrochloride, Rifampin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
75
States / cities
Birmingham, Alabama • Los Angeles, California • Oakland, California + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 10, 2026, 4:50 PM EDT
Completed Phase 3 Interventional Results available

TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens

NCT02410772
View directory record Official record
Conditions
Tuberculosis
Interventions
rifapentine, rifapentine and moxifloxacin, control
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
12 Years and older
Enrollment
2,516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
5
States / cities
San Francisco, California • New York, New York • Fort Worth, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 10, 2026, 4:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Test the Effects of Itraconazole and Carbamazepine on OPC-167832 in Healthy Men and Women

NCT07542847
View directory record Official record
Conditions
Healthy Volunteers
Interventions
OPC-167832, Itraconazole, Carbamazepine
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 10, 2026, 4:50 PM EDT
Terminated No phase listed Observational

CD8 Reactivity to Microorganisms in Blood and Breast Milk

NCT03084614
View directory record Official record
Conditions
Immune Modulation, Tuberculosis, Leprosy, Pertussis, Lyme Disease
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced Oct 10, 2026, 4:50 PM EDT
Completed Phase 2 Interventional

Interferon Gamma for Drug Resistant Tuberculosis

NCT00001407
View directory record Official record
Conditions
Pneumonia, Pulmonary Tuberculosis
Interventions
Interferon Gamma
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 10, 2026, 4:50 PM EDT
Completed No phase listed Observational

Evaluation of Non-Inferiority of Two Fast Follower Nucleic Acid Amplification Tests

NCT02252198
View directory record Official record
Conditions
Tuberculosis
Interventions
Epistem Genedrive® and MolBio Truenat™
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 10, 2026, 4:50 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Clinical Trial of the Safety, Pharmacokinetics and Hematologic Effects of Imatinib on Myelopoiesis in Adults When Given With and Without Isoniazid and Rifabutin

NCT03891901
View directory record Official record
Conditions
Tuberculosis
Interventions
Imatinib, Isoniazid, Rifabutin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 10, 2026, 4:50 PM EDT
Completed No phase listed Observational

Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and Adults

NCT05283967
View directory record Official record
Conditions
Tuberculosis
Interventions
urine colorimetric assay
Diagnostic Test
Lead sponsor
University of Virginia
Other
Eligibility
4 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Newark, New Jersey • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 10, 2026, 4:50 PM EDT
Terminated Phase 3 Interventional

ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension

NCT06418711
View directory record Official record
Conditions
MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
Interventions
Clofazimine Inhalation Suspension, Placebo
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 85 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
54
States / cities
Birmingham, Alabama • Fresno, California • Los Angeles, California + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 10, 2026, 4:50 PM EDT
Completed Phase 1 Interventional

Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis

NCT00004736
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Nelfinavir mesylate, Ethambutol hydrochloride, Isoniazid, Pyrazinamide, Lamivudine, Rifabutin, Stavudine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
10
States / cities
Los Angeles, California • San Diego, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2008 · Synced Oct 10, 2026, 4:50 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects

NCT04551573
View directory record Official record
Conditions
Tuberculosis, Hiv
Interventions
Rifapentine daily, Rifapentine weekly
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 20, 2021 · Synced Oct 10, 2026, 4:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Single-Dose Study to Evaluate the PKs of Pretomanid in Participants With Renal Impairment Compared to Participants With Normal Renal Function

NCT03896750
View directory record Official record
Conditions
Renal Impairment, Tuberculosis
Interventions
PA-824
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
3
States / cities
Miami, Florida • St Louis, Missouri • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 10, 2026, 4:50 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Effects of SQ109 on QTc Interval in Healthy Subjects

NCT01874314
View directory record Official record
Conditions
Tuberculosis
Interventions
SQ109, SQ109 Placebo, Moxifloxacin
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 24, 2014 · Synced Oct 10, 2026, 4:50 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

PK Interaction Between Rifapentine or Rifampicin and a Single Dose of TMC207 in Healthy Subjects (TMC207-CL002)

NCT02216331
View directory record Official record
Conditions
Tuberculosis
Interventions
TMC207, rifapentine, rifampicin
Drug
Lead sponsor
Global Alliance for TB Drug Development
Other
Eligibility
19 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 10, 2026, 4:50 PM EDT
Withdrawn Not applicable Interventional

Vitamin D in Active Tuberculosis (TB) Study

NCT00788320
View directory record Official record
Conditions
Tuberculosis
Interventions
Vitamin D3, Placebo
Drug
Lead sponsor
Atlanta VA Medical Center
Federal
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 20, 2012 · Synced Oct 10, 2026, 4:50 PM EDT
Completed Phase 4 Interventional Results available

Immediate Versus Deferred Start of Anti-HIV Therapy in HIV-Infected Adults Being Treated for Tuberculosis

NCT00108862
View directory record Official record
Conditions
HIV Infection, Tuberculosis
Interventions
Strategy: Immediate ART, Strategy: Deferred ART
Other
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
13 Years and older
Enrollment
809 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
4
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Oct 10, 2026, 4:50 PM EDT
Completed Not applicable Interventional

Metabolism of Antituberculosis Drugs in HIV-Infected Persons With Tuberculosis

NCT00000950
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Ethambutol hydrochloride, Isoniazid, Pyrazinamide, Pyridoxine hydrochloride, Rifampin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
13
States / cities
Los Angeles, California • Torrance, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2011 · Synced Oct 10, 2026, 4:50 PM EDT
Completed Not applicable Interventional

TBTC Study 23: Treatment of HIV-Related Tuberculosis Using a Rifabutin-Based Regimen

NCT00023361
View directory record Official record
Conditions
HIV Infections, Tuberculosis
Interventions
Rifabutin
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2005 · Synced Oct 10, 2026, 4:50 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Dose Study of Tuberculin Purified Protein Derivative (JHP/Dose)

NCT01689831
View directory record Official record
Conditions
Tuberculosis Infection
Interventions
To confirm the potency of Aplisol formulated with newly produced Tuberculin PPD compared to PPD-S2 standard., Reactivity of Aplisol compared to reference standard PPD-S2.
Biological
Lead sponsor
JHP Pharmaceuticals LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2012 · Synced Oct 10, 2026, 4:50 PM EDT
Completed No phase listed Observational

TBTC NAA Study: Pilot Study of Surrogate Markers for Outcome of TB Treatment

NCT00023439
View directory record Official record
Conditions
Tuberculosis
Interventions
Nucleic Acid Amplification Methods for diagnosis
Other
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
10
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2011 · Synced Oct 10, 2026, 4:50 PM EDT